Stock Scorecard



Stock Summary for Novo Nordisk (NVO) - $36.85 as of 4/6/2026 8:47:39 AM EST

Total Score

14 out of 30

Safety Score

63 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for NVO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for NVO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for NVO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for NVO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for NVO (63 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 8
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for NVO

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight 4/4/2026 11:52:00 AM
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison 4/3/2026 2:40:00 AM
Wegovy vs. Foundayo: Novo Nordisk’s “Record-Breaking” Run Meets the Eli Lilly (LLY) Challenge 4/2/2026 3:10:00 PM
FDA approves Lilly obesity pill, triggering battle with Novo Nordisk 4/2/2026 3:09:00 AM
Lilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo 4/2/2026 3:09:00 AM
Jim Cramer on Eli Lilly's recent moves to top Novo Nordisk in the weight loss space 4/2/2026 3:09:00 AM
Novo Nordisk cuts Ozempic, Wegovy prices in India again to fight cheaper generics 4/1/2026 2:39:00 PM
KBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo Nordisk 4/1/2026 6:09:00 AM
Novo Nordisk Launches Discounted Subscription Program for Wegovy 3/31/2026 2:39:00 PM
Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year 3/31/2026 2:39:00 PM

Financial Details for NVO

Company Overview

Ticker NVO
Company Name Novo Nordisk
Country USA
Description Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 12/31/2025
Next Earnings Date 5/6/2026

Stock Price History

Last Day Price 36.85
Price 4 Years Ago 62.22
Last Day Price Updated 4/6/2026 8:47:39 AM EST
Last Day Volume 14,695,847
Average Daily Volume 24,417,123
52-Week High 77.68
52-Week Low 34.58
Last Price to 52 Week Low 6.56%

Valuation Measures

Trailing PE 10.39
Industry PE 28.25
Sector PE 65.47
5-Year Average PE 15.81
Free Cash Flow Ratio 4.68
Industry Free Cash Flow Ratio 26.60
Sector Free Cash Flow Ratio 27.44
Current Ratio Most Recent Quarter 0.80
Total Cash Per Share 7.87
Book Value Per Share Most Recent Quarter 6.76
Price to Book Ratio 5.44
Industry Price to Book Ratio 11.26
Sector Price to Book Ratio 36.09
Price to Sales Ratio Twelve Trailing Months 0.53
Industry Price to Sales Ratio Twelve Trailing Months 3.20
Sector Price to Sales Ratio Twelve Trailing Months 4.98
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 3,363,575,000
Market Capitalization 123,947,738,750
Institutional Ownership 9.50%

Dividends

Ex-Dividend Date 3/30/2026
Previous Dividend Amount 0.5843
Current Dividend Amount 1.2174
Total Years Dividend Increasing 6
Trailing Annual Dividend Rate 1.80
Trailing Annual Dividend Yield 4.87%
Forward Annual Dividend Rate 2.43
Forward Annual Dividend Yield 6.58%
5-Year Dividend Payments Count 10
3-Year Average Dividend Yield 3.51%
5-Year Average Dividend Yield 1.91%
1-Year Dividend Growth Rate Percentage 40.99%
3-Year Dividend Growth Rate Percentage 18.74%
5-Year Dividend Growth Rate Percentage 32.08%
All-Time Dividend Growth Rate Percentage 10.45%
Dividend Payout Ratio 50.61%

Income Statement

Quarterly Earnings Growth YOY -4.70%
Annual Earnings Growth -2.46%
Reported EPS 12 Trailing Months 3.56
Reported EPS Past Year 0.00
Reported EPS Prior Year 23.03
Net Income Twelve Trailing Months 102,193,037,000
Net Income Past Year 98,500,286,000
Net Income Prior Year 100,988,000,000
Quarterly Revenue Growth YOY -7.60%
5-Year Revenue Growth 18.55%
Operating Margin Twelve Trailing Months 44.50%

Balance Sheet

Total Cash Most Recent Quarter 26,464,000,000
Total Cash Past Year 26,464,000,000
Total Cash Prior Year 15,655,000,000
Net Cash Position Most Recent Quarter -92,477,000,000
Net Cash Position Past Year -92,477,000,000
Long Term Debt Past Year 118,941,000,000
Long Term Debt Prior Year 84,246,000,000
Total Debt Most Recent Quarter 118,941,000,000
Equity to Debt Ratio Past Year 0.62
Equity to Debt Ratio Most Recent Quarter 0.62
Total Stockholder Equity Past Year 194,047,000,000
Total Stockholder Equity Prior Year 143,486,000,000
Total Stockholder Equity Most Recent Quarter 194,047,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 56,184,000,000
Free Cash Flow Per Share Twelve Trailing Months 16.70
Free Cash Flow Past Year 28,989,000,000
Free Cash Flow Prior Year 69,659,000,000

Options

Put/Call Ratio 0.60
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.66
MACD Signal -2.17
20-Day Bollinger Lower Band 30.38
20-Day Bollinger Middle Band 46.41
20-Day Bollinger Upper Band 62.44
Beta 0.26
RSI 39.88
50-Day SMA 53.89
150-Day SMA 84.15
200-Day SMA 77.74

System

Modified 4/4/2026 4:53:56 AM EST